BIOYF / RX.V continues to be a potential multi-bagger home run IMO. Here's why:

(1) BIOYF / RX.V is debt-free, cash-rich making money hand over fist compared to its tiny market cap and growing rapidly. Their key product, Feramax, is getting rave reviews by pharmacists, doctors, and users.

(2) Last quarter they had +.02 EPS. Annualized + growth makes them appear cheap to me especially vs. future increased potential EPS.

(3) Their profit margins are extremely high.

(4) RX.V / BIOYF launched a new product recently in addition to another product for its Feramax line. The new product, Cathejell, already has two long term hospital supply contracts.

(5) Insiders have bought shares in the open market several times.